



STAR BRIGHT

An Alzheimer's Disease Clinical Study

Aim

To assess whether the research drug, Lu AE58054, given in addition to current medication (donepezil, rivastigmine or galantamine) can improve cognitive function (memory, thinking and reasoning) in patients with Alzheimer's disease (AD)

Hypothesis

AD is a chronic, progressive disease which gradually destroys memory and the ability to learn, reason, make judgments, communicate and carry out daily activities. Lu AE58054 helps the nerve cells in the brain work together and improves cognitive function when given with other AD treatments (donepezil/rivastigmine/galantamine)

The Study

A phase III, randomised, double-blind, parallel-group, placebo-controlled study of Lu AE58054 in patients with mild-moderate AD treated with an acetylcholinesterase inhibitor (AChEI)

Status

Enrolment to commence August 2014

Clinical Trial No. NCT 02006654

Funding

- Lundbeck Australia Pty Ltd
- Neurodegenerative Disorders Research Pty Ltd

Criteria

To be eligible for the Starbright Study participants must:

- have been diagnosed with probable AD,
- be at least 50 years old,
- have a Mini Mental State Exam score of 12–22,
- be on a stable dose of AChEI (donepezil, rivastigmine or galantamine) for 4 months,
- be able to provide informed consent,
- have a reliable and willing caregiver,
- be willing to provide blood samples,
- be able to take oral medication, and
- not be pregnant, lactating or become pregnant.

Ethics approval

Bellberry Human Research Ethics Committee

Contact

Professor Peter K Panegyres, MD PhD FRACP
Principal Investigator
Neurodegenerative Disorders Research Pty Ltd
4 Lawrence Avenue, West Perth WA 6005

Phone: (08) 9481 6293
Fax: (08) 9481 6294
Email: research@ndr.org.au